Poland· PL-100381772
Glyxambi
A linagliptin and empagliflozin product containing empagliflozinum + linagliptinum, registered in Poland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Linagliptin and empagliflozin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Linagliptin and empagliflozin · ATC A10BD19
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Empagliflozinum + Linagliptinum
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Poland (PL)
- ATC code
- A10BD19
- ATC class
- Linagliptin and empagliflozin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 9
- gtin05909991308636
- gtin05909991308643
- gtin05909991308650
- gtin05909991308667
- gtin05909991308674
- gtin05909991308681
- gtin05909991308698
- gtin05909991308704
- gtin05909991308711
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linagliptin and empagliflozin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLYXAMBIBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
- SpainGLYXAMBI 10 MG/5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- United KingdomGlyxambi 10mg/5mg tabletsBoehringer Ingelheim Ltd
- IrelandGlyxambi 10 mg/5 mg film-coated tabletsBoehringer Ingelheim International GmbH
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NetherlandsGlyxambi 10 mg/ 5 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Glyxambi
- Liechtenstein · Glyxambi
- Norway · Glyxambi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f5c59e83-9ff7-4130-b23c-fb2361597dd7 GET /v1/drugs/f5c59e83-9ff7-4130-b23c-fb2361597dd7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "25 mg + 5 mg",
"packaging": "05909991308636 ¦ Rp ¦ EU/1/16/1146/010 ¦ 119377\n7 tabl.\n05909991308643 ¦ Rp ¦ EU/1/16/1146/011 ¦ 119378\n10 tabl.\n05909991308650 ¦ Rp ¦ EU/1/16/1146/012 ¦ 119379\n14 tabl.\n05909991308667 ¦ Rp ¦ EU/1/16/1146/013 ¦ 119380\n28 tabl.\n05909991308674 ¦ Rp ¦ EU/1/16/1146/014 ¦ 119381\n30 tabl.\n05909991308681 ¦ Rp ¦ EU/1/16/1146/015 ¦ 119382\n60 tabl.\n05909991308698 ¦ Rp ¦ EU/1/16/1146/016 ¦ 119383\n70 tabl.\n05909991308704 ¦ Rp ¦ EU/1/16/1146/017 ¦ 119384\n90 tabl.\n05909991308711 ¦ Rp ¦ EU/1/16/1146/018 ¦ 119385\n100 tabl.",
"substance": "Empagliflozinum 25 mg + Linagliptinum 5 mg",
"common_name": "Empagliflozinum + Linagliptinum",
"pl_product_id": "100381772",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.